Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Intervalo de año de publicación
1.
Pak J Pharm Sci ; 33(1(Special)): 409-415, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-32173635

RESUMEN

As a new oral anticoagulant, rivaroxaban is equivalent to warfarin in preventing and treating thromboembolism, but it can significantly reduce the occurrence of severe bleeding and fatal organ bleeding. This article analyzes the clinical efficacy and drug safety of rivaroxaban in the prevention and treatment of senile thromboembolic disease. The results showed that after treatment, acute thrombosis disappeared in patients with acute venous thrombosis, and no new or recurrent venous thrombosis, pulmonary embolism and death occurred. In the rivaroxaban group, 3 cases of fecal occult blood were positive at 6 months and the incidence rate was 7%. During the follow-up period, there were no significant changes in laboratory blood tests for coagulation, hemoglobin, platelet and liver and kidney function during the follow-up observation of the rivaroxaban group and between the rivaroxaban group and the warfarin group (P>0.05). Therefore, oral rivaroxaban is an effective method for the prevention and treatment of elderly patients with thromboembolic disease. Daily 10mg rivaroxaban is a safe and effective dose for the prevention and treatment of elderly patients with thrombotic diseases. The efficacy of rivaroxaban is equivalent to that of warfarin. However, the treatment is easier with better compliance and safety.


Asunto(s)
Inhibidores del Factor Xa/uso terapéutico , Rivaroxabán/uso terapéutico , Tromboembolia/prevención & control , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Rivaroxabán/efectos adversos , Tromboembolia/sangre , Tromboembolia/tratamiento farmacológico , Resultado del Tratamiento
2.
Artículo en Chino | WPRIM (Pacífico Occidental) | ID: wpr-660817

RESUMEN

Objective To systemic evaluate postoperative pulmonary function between segmentectomy and lobectomy in patients with early stage non-small cell lung cancer.Methods Computer searched was performed up to September 2016 at the Cochrane Library,PubMed,EMBASE,CBM,CNKI,VIP and Wanfang database,collected postoperative pulmonary function between segmentectomy and lobectomy in Patients with early stage Non-Small Cell Lung Cancer.Study selection,data collection and critical assessment of the included studies were performed according to the recommendations of the Cochrane Collaboration.Results Eight studies included 308 segmentectomy and 386 lobectomy were identified for inclusion.FVC% (MD =9.91,95% CI:3.53-16.30,P =0.002),postoperation / preoperation FVC% (MD =6.74,95% CI:5.52-7.79,P <0.05),FEV1% (MD =13.25,95% CI:10.25-16.26,P < 0.05),postoperation / preoperation FEV1% (MD =7.18,95 % CI:5.88-8.48,P < 0.05) showed significant difference.Conclusion Pulmonary function index was superior to lobectomy after segmentectomy in patients with early stage lung cancer,and segmentectomy resection was more beneficial to preserve lung function.

3.
Artículo en Chino | WPRIM (Pacífico Occidental) | ID: wpr-662824

RESUMEN

Objective To systemic evaluate postoperative pulmonary function between segmentectomy and lobectomy in patients with early stage non-small cell lung cancer.Methods Computer searched was performed up to September 2016 at the Cochrane Library,PubMed,EMBASE,CBM,CNKI,VIP and Wanfang database,collected postoperative pulmonary function between segmentectomy and lobectomy in Patients with early stage Non-Small Cell Lung Cancer.Study selection,data collection and critical assessment of the included studies were performed according to the recommendations of the Cochrane Collaboration.Results Eight studies included 308 segmentectomy and 386 lobectomy were identified for inclusion.FVC% (MD =9.91,95% CI:3.53-16.30,P =0.002),postoperation / preoperation FVC% (MD =6.74,95% CI:5.52-7.79,P <0.05),FEV1% (MD =13.25,95% CI:10.25-16.26,P < 0.05),postoperation / preoperation FEV1% (MD =7.18,95 % CI:5.88-8.48,P < 0.05) showed significant difference.Conclusion Pulmonary function index was superior to lobectomy after segmentectomy in patients with early stage lung cancer,and segmentectomy resection was more beneficial to preserve lung function.

4.
Int J Gynecol Cancer ; 19(7): 1182-5, 2009 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-19820387

RESUMEN

OBJECTIVE: : To investigate the effect of aspirin on human Ishikawa adenocarcinoma endometrium cell proliferation and apoptosis and its related mechanism through in vitro experiments. METHODS: : The effects on Ishikawa adenocarcinoma endometrium cell proliferation and cell cycle of aspirin at different intervals and concentrations were determined with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide method and flow cytometry; cell morphous change after the effect of aspirin was observed with transmission electron microscope; and the effect of aspirin on B-cell lymphoma/leukemia-x, long (Bcl-xl) proteinum expression was determined with Western blot. RESULTS: : Aspirin had a significant depressant effect on human Ishikawa adenocarcinoma endometrium cell proliferation, and the effect showed time and dose dependence (P < 0.05). Aspirin-induced cell blockage at G1 phase, elevated cell apoptosis rate, and its effect were related with its concentration (P < 0.05). After treatment, cell volume was reduced, chromatin was seen concentrated and aggregated around the edge of nuclear membrane, and apoptotic body was formed. Aspirin decreased Bcl-xl proteinum expression, and the effect was related with its concentration (P < 0.05). CONCLUSIONS: : Aspirin has a distinct depressant effect on human Ishikawa adenocarcinoma endometrium cell growth, and its effect may be realized by lowering Bcl-xl proteinum expression.


Asunto(s)
Adenocarcinoma/patología , Aspirina/farmacología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Neoplasias Endometriales/patología , Adenocarcinoma/metabolismo , Apoptosis/efectos de los fármacos , Ciclo Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Regulación hacia Abajo/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Neoplasias Endometriales/metabolismo , Femenino , Humanos , Factores de Tiempo , Proteína bcl-X/metabolismo
5.
Artículo en Chino | WPRIM (Pacífico Occidental) | ID: wpr-541501

RESUMEN

Objective:To analyze a novel epitope of Homo sapiens synapse associated protein and synthesize polyclonal antibody.Methods:FRG4 full-length sequence was obtained by PCR from human fetal liver library;by bioinformatics to detect the second structure of amino acids encoded by FRG4 and its epitope and motifs;by solid-phase peptide synthesis method to synthesize FRG4 peptides,then peptides were immunized to rabbits;by immunohistory to detect the expression of FRG4 in HepG_2 cells.Results:Select 13-peptides PKLVKEEVFWRNY by bioinformatics to synthesize rabbit anti-human FRG4 polyclonal antibody.Antibody purity was 82.79% and antibody dilution was 1∶16 000 detected by ELISA.The antibody had a good reaction and speciality in Western blot,it was mainly expressed in cytoplasm of HepG_2 cells.Conclusion:A novel Homo sapiens synapse associated protein(FRG4) antibody was synthesized successfully.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA